Objective: nab-Paclitaxel has been shown to disrupt pancreatic cancer stroma and was effective in combination with gemcitabine in a phase I/II trial. This study was designed to determine the efficacy of nabpaclitaxel monotherapy in previously treated pancreatic cancer patients.
P ancreatic cancer is the fourth leading cause of cancer death in the United States with an estimated new cases of 42,470 and 35,240 deaths annually. 1 The 5-year survival rate for patients with resectable disease is 20%, and only 2% of the patients with advanced or metastatic disease survive for 5 years or longer. 1 Gemcitabine and erlotinib are the only 2 Food and Drug Administration-approved systemic chemotherapeutic options for patients with advanced pancreatic cancer in the United States. 2 Gemcitabine-based therapy results in a median overall survival (OS) of 6 to 7 months. Recently, the results of the PRODIGE 4/ACCORD 11 trial were reported, showing significant efficacy of a non-gemcitabine-based regimen in patients with advanced pancreatic cancer. 3 In this randomized phase III trial, the combination cytotoxic regimen FOLFIRINOX [5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin] was superior to gemcitabine monotherapy as first-line therapy for patients with advanced disease and a good performance status. The median OS for the patients treated with FOLFIRINOX in this study was an impressive 11.1 months versus 6.8 months with gemcitabine (P < 0.0001; hazard ratio, 0.57).
For patients who progressed on the first-line therapy, even fewer options exist. There is no standard treatment in the second-line setting and only 1 positive randomized phase III trial has been reported to date-the CONKO-003 study. 4 In this study, 168 patients were randomized to either 5-FU/folinic acid (FF) or 5-FU/FF plus oxaliplatin. The FF plus oxaliplatin regimen produced a statistically superior OS (26 vs. 13 wk, P = 0.014) and progression-free survival (PFS) (13 vs. 9 wk, P = 0.012. 5 
)
The stromal component of the tumor may play a central role in the chemoresistance in pancreatic cancer. 6, 7 A stromaldepleting agent, IPI-926, an inhibitor of the hedgehog signaling pathway in the stromal cells has recently shown promise in overcoming this obstacle. 8 Another emerging stromal target appears to be SPARC (secreted protein acid rich in cysteine). Pancreatic cancer cells and their surrounding stroma are known to express SPARC, and the overexpression of this protein has been associated with worse OS. 9 nab-Paclitaxel is a cremophor-free, albumin-bound 130-nm nanoparticle (nab) form of paclitaxel which can breach the blood-stroma barrier to reach the tumor cell by targeting the albumin receptor (gp60)mediated transcytosis pathway using caveolin-1 activated caveolar transport. Once in the stromal microenvironment, nab-paclitaxel may be preferentially localized by SPARC, which can enhance drug delivery to the tumor. 10 Preclinical studies have demonstrated a collapse of the stromal component of pancreatic tumors after nab-paclitaxel therapy, leading to enhanced drug delivery to the tumor cells. 11 nab-Paclitaxel in combination with gemcitabine was well tolerated in advanced pancreatic cancer patients in a phase I/II study and showed preliminary evidence of an antitumor activity. 12 The current study was designed to determine the effectiveness of nab-paclitaxel monotherapy as a second-line agent in patients with pancreatic cancer.
METHODS

Study Design and Objectives
A single-arm, open-label phase II clinical trial of nabpaclitaxel in patients with advanced pancreatic cancer, who progressed on gemcitabine-based therapy was conducted at the Sylvester Comprehensive Cancer Center in Miami, FL. The primary endpoint was the 6-month OS rate, defined as the proportion of patients alive at 6 months from the start of their study treatment. Secondary endpoints included response rate, duration of response, PFS, safety, and tolerability. Exploratory endpoints were also planned a priori to attempt to correlate serum cancer antigen 19-9 (CA19-9) levels and tumoral SPARC expression with outcome. The trial was conducted in compliance with the Declaration of Helsinki and the Guidelines of Good Clinical Practice. The University of Miami Institutional Review Board approved the protocol and each patient provided the written informed consent before registration and treatment. The study was registered at www.ClinicalTrials.gov (identifier NCT00691054).
Eligibility
Patients of at least 18 years of age, with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2, and a histologic diagnosis of pancreatic adenocarcinoma who were able to give informed consent were screened for enrollment. Patients with unresectable locally advanced or metastatic disease were eligible, and had to have progression within 6 months of gemcitabine-based therapy. This definition allowed patients who had a recurrence within 6 months of a gemcitabine-based adjuvant regimen to be included. Additional inclusion criteria required adequate organ function with neutrophils Z1.5 Â10 9 /L, hemoglobin Z9.0 g/dL, platelets Z100Â 10 9 /L, bilirubin r1.5 times the upper limit of normal, serum transaminases (serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase) r2.5 times upper limit of normal, and creatinine r1.5 mg/dL. Both men and women of child-bearing potential had to agree to use contraception throughout the study period.
Patients were excluded if they had a life expectancy of less than 3 months, or had any systemic chemotherapy or radiation within the last 3 weeks, or major surgery within 4 weeks. Patients with grade 2 or higher peripheral neuropathy, New York Heart Association grade II or higher congestive heart failure, a myocardial infarction or stroke within the last 3 months, concurrent active malignancies (with the exception of in situ carcinoma of the cervix and inactive nonmelanoma skin cancer), or human immunodeficiency virus infection were also excluded. Pregnant or breastfeeding women were also not eligible.
Treatment Plan
Baseline evaluation to confirm the eligibility included, a complete medical history and physical examination with assessment of the ECOG PS. Blood was obtained for complete blood cell counts, comprehensive metabolic panel, and CA19-9 level, and urine for a pregnancy test when appropriate. Contrast-enhanced computed tomography scans of the chest, abdomen, and pelvis were also obtained within 4 weeks before the study entry.
nab-Paclitaxel was administered on an outpatient basis at a dose of 100 mg/m 2 intravenously on days 1, 8, and 15 of a 28-day cycle. Each dose was capped at a body surface area of 2.0 m 2 and the dose was given over 30 minutes. Patients were followed for adverse events throughout the study period and these were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. 13 Dose reduction or delay allowed for hematological toxicity are as follows: for the first episode of neutropenic fever, grade 2 or higher neutropenia on day 1 or grade 3 or higher neutropenia on days 8 or 15; the next dose was held until recovery to grade 1; and therapy was resumed at the same dose with the support of the granulocyte-colony stimulating factor (G-CSF). G-CSF was given at a dose of 5 mg/kg subcutaneously on days 2 to 5, 9 to 12, and 16 to 19 as per necessity. If there was a second occurrence of any of these toxicities, the next dose was held until recovery to grade 1 and all subsequent doses were reduced to 75 mg/m 2 . For a third occurrence, the next dose was held until recovery to grade 1, and all subsequent doses were reduced to 50 mg/m 2 . No further dose reductions were allowed.
In the case of grade 3 or 4 thrombocytopenia, the subsequent doses were held until there was recovery to grade 1 and therapy was resumed at 75 mg/m 2 . For grade 2 or 3 peripheral neuropathy, therapy was not delayed but subsequent doses were reduced to 75 mg/m 2 . For grade 4 peripheral neuropathy, therapy was delayed until recovery to grade 1 and subsequent doses were reduced to 50 mg/m 2 .
Response Assessment
Contrast-enhanced computed tomography scans of the chest, abdomen, and pelvis were performed every 8 weeks on therapy (every 2 cycles) or sooner if clinically indicated. Treatment was continued until documented progression of the disease, intolerable toxicity, or withdrawal of consent. Responses were assessed according to the Response Evaluation Criteria in Sold Tumors guidelines. 14 
Correlative Studies
Serum CA19-9 levels were measured at baseline and at the end of every 2 cycles of the therapy. To explore the correlation between SPARC expression and outcome, patients were asked to give consent for their formalin-fixed, paraffinembedded biopsy specimens to be tested for SPARC expression by immunohistochemistry (IHC). These tumor specimens were sent to Caris Life Sciences Target Now Molecular Profiling Laboratories (Phoenix, AZ) for SPARC IHC evaluation. Each specimen was subjected to the standard IHC processing and were incubated separately with a mouse antihuman SPARC monoclonal antibody (R&D Systems, Minneapolis, MN) and a rabbit anti-human SPARC polyclonal antibody (Exalpha Biologicals Inc., Shirley, MA). The laboratory established a cutoff of Z2+ (on a scale of 0, 1+, 2+, or 3+) and Z30% of cells staining positive for a specimen to be labeled as SPARC positive. The laboratory was blinded to the patient outcome.
Statistical Methods
The study size of 20 patients was based on the feasibility of completing study enrollment within 18 months, a maximum study duration of 3 years, including a minimum follow-up of 9 months. The primary endpoint of this study was the 6-month OS rate. We hypothesized that nab-paclitaxel would show sufficient efficacy to achieve a median OS of at least 4.6 months, which corresponds to a 6-month OS rate of 41%, assuming exponential survival. A study size of 20 patients would give a 95% confidence interval (95% CI) for the true 6-month OS of 18.5% to 61.5% if the observed 6-month OS rate was 40%.
PFS and OS were measured from the start of the study treatment. PFS was defined as the elapsed time to documented evidence of disease progression or death from any cause, whichever was earlier. Patients known to be alive and without progressive disease, were censored at the date of the last documented progression-free status. OS was defined as the elapsed time to death from any cause or last contact (censored observations). PFS and OS were estimated by the Kaplan-Meier method with the corresponding 2-sided 95% CI's for survival proportions based on Greenwood variance and the log-transform method. 15 Response rate was estimated by the exact 95% CI.
The University of Miami Data Safety Monitoring Committee performed interim analyses throughout the course of the study with predefined stopping rules if an excess of death, toxicity, or lack of clinical benefit was found.
This was an investigator-initiated trial sponsored by the Abraxis BioScience Inc., the manufacturer of nab-paclitaxel. The investigators collected and managed the raw data and performed the data analysis. The investigators were responsible for the decision to publish the results of the study. The sponsor did not have access to the raw data, and did not coauthor the manuscript, but did approve the final version. The authors vouch for the completeness and accuracy of the data and the data analyses.
RESULTS
Patient Characteristics
The planned 20 patients were accrued over a 9-month period between July 2008 and April 2009. One patient had a sudden clinical deterioration after being enrolled and never received study drug and was therefore not included in subsequent analyses. Table 1 shows the baseline characteristics of the study patients. The median age was 61 years and 79% had an ECOG PS of 0 or 1. One patient had stage III unresectable disease at the time of diagnosis and progressed after the firstline therapy, but still had nonmetastatic disease at the time of enrollment. The remaining patients had metastatic disease at the time of entry. Four patients (21%) were eligible based on progression within 6 months of gemcitabine-containing adjuvant therapy and received this study therapy as their first-line treatment for recurrent disease. Two patients received nongemcitabine-based frontline therapy (Table 1 ) and were granted exceptions to be enrolled for this trial.
At the time the database was locked for analysis on August 30, 2010, 15 patients had progressed on therapy and died, 2 had progressed on therapy but remained alive, 1 patient with stable disease (SD) withdrew because of deteriorating performance status (and subsequently died), and 1 patient was still receiving nab-paclitaxel with SD on cycle 23 of the therapy. Among the 18 patients with treatment failure, 10 went on to receive subsequent lines of chemotherapy, including FOLFOX, capecitabine/oxaliplatin, and other investigational therapies available at our institution. One patient who went on to receive the third-line chemotherapy with FOLFOX achieved a complete radiologic response in the metastases to the liver and was then taken for a pancreaticoduodenectomy which demonstrated a complete pathologic response to the therapy.
Treatment Delivery and Toxicity
nab-Paclitaxel monotherapy on a 3-week on and 1-week off schedule was generally well tolerated in this study. A total of 81 cycles were delivered among the 19 patients treated with a median number of cycles of 2 (range, 1 to 23). The median dose intensity, defined as the total number of doses delivered over total number of doses prescribed, was 92%. The only toxicity that resulted in dose modification or delay was neutropenia. This occured infrequently, with 13 of a planned 243 doses (5%) being omitted for neutropenia. In all of these cases, a short course of G-CSF allowed these patients to receive subsequent planned doses. There was only 1 case of dose reduction for recurrent neutropenia despite the G-CSF support. Five patients (26%) experienced grades 3-4 neutropenia, 2 (11%) had grades 3-4 anemia, and 2 (11%) had neutropenic fever. There was only 1 episode of grade 3 or 4 nonhematological toxicity (hypocalcemia) and there were no episodes of grades 3-4 peripheral neuropathy. Table 2 summarizes the most common adverse events observed in this study. Efficacy Sixteen patients had died and 3 patients were alive at time of this analysis. Two of these surviving patients progressed after 2 cycles of the therapy, and were alive at 17.6 and 23.7 months follow-up. The third patient was alive and progression free at 20.7 months follow-up, still receiving nab-paclitaxel. The primary endpoint of the 6-month OS was 57.9% (95% CI, 33.2%-76.3%). The estimated median OS was 7.3 months (95% CI, 2.8-15.8 mo), and the 12-and 18-month OS rates were 36.8% (95% CI, 16.5%-57.5%) and 21.1% (95% CI, 6.6%-41%), respectively. The estimated median PFS was 1.7 months (95% CI, 1.5-3.5 mo), and the PFS rates at 6 and 12 months were 15.8% (95% CI, 3.9%-34.9%) and 5% (95% CI, 04%-21.4%), respectively. Kaplan-Meier plots for PFS and OS are shown in Figures 1A and B , respectively. Among the 19 patients analyzed, there was 1 (5%) with a confirmed partial response (PR) and 6 (32%) with SD, giving an overall response rate of 5% and a clinical benefit rate (PR+SD) of 37%. The remaining 12 patients (63%) had progression or death on or before their first-response assessment. Table 3 summarizes the efficacy endpoints in this trial.
Correlative Studies
CA19-9 response, defined as a decrease of at least 50% from baseline level, was assessed in 14 patients who had baseline elevation in CA19-9 (>35 U/mL), and at least 1 postbaseline measurement (median 3 measurements; range, 1 to 9). The CA19-9 response rate was 50% overall. There was no significant association between clinical benefit and CA19-9 response. Among 7 CA19-9 responders, 3 had clinical benefit (1 with PR and 2 with SD), compared with 2 patients with SD among the 7 nonresponders (42.9% vs. 28.6%, P = 1.0 by Fisher exact test).
With respect to PFS, there was no significant difference by CA 19-9 response (P = 0.916, Fig. 1C ). However, the 7 CA19-9 responders had a significantly better OS than the 7 nonresponders, median 13.8 (95% CI, 2.8 to not reached) versus 6.9 months (95% CI, 1.9-13.3), respectively, (log rank P = 0.042, Fig. 1D ).
Among the 19 patients treated, 15 had formalin-fixed, paraffin-embedded tumor specimens available for SPARC IHC testing. In the remaining 4 patients, there was insufficient tissue left from the diagnostic specimens to perform IHC. Figure 2 shows 2 representative specimens with positive and negative staining for SPARC (2B and 2D, respectively). Only 2 of the 15 tumors stained positive for SPARC. Neither of these patients had clinical benefit (PR or SD). Figure 3 shows the relationship between SPARC expression and PFS. The number of SPARC-positive patients was too small to perform statistical testing on the predictive value of SPARC expression on any endpoints.
DISCUSSION
The primary aim of this study was achieved with the demonstration of a 6-month OS rate of 57.9% (95% CI, 33.2%-76.3%), which exceeded the prespecified mark that was set for efficacy. The activity seen in this trial was modest but there appeared to be a subset of patients who achieved meaningful clinical benefit with disease stabilization for a period of time which exceeded the expected survival in this population. Although there is no uniformly accepted chemotherapy regimen for second-line therapy in advanced pancreatic cancer, the benchmark for progression on second-line therapy can be extrapolated from historical controls in the CONKO-003 trial. 4 In that study, the median PFS was 13 weeks in the experimental arm. 5 In our study, the median PFS was only 7 weeks but there were 7 patients (37%) who survived longer than 13 weeks. One noteworthy finding in our study was the wide gap between the median PFS and median OS (1.7 vs. 7.3 mo). This may have been due to the inherent selection bias of a single-institution trial. We adopted an aggressive approach by offering additional therapy including clinical trials to patients like these who still have a good performance status and may benefit from an investigational agent or new combination. The most commonly used third-line therapy after patients progressed on this trial was FOLFOX. In addition to offering further treatment to patients with a good performance status, the OS results may have also been favorably affected by the inclusion of patients who recurred within 6 months of gemcitabine-based adjuvant therapy.
This study also showed that nab-paclitaxel was well tolerated as a second-line monotherapy for patients with advanced pancreatic cancer. Dose reduction was only necessary in 1 patient for recurrent grade 4 neutropenia despite G-CSF. The nonhematological toxicities were mild and manageable. No grade 3 peripheral neuropathy was observed. Only 1 patient was taken off study for declining performance status, considered to be unrelated to the therapy. No patients were taken off study for toxicity. One patient continues on therapy for nearly 2 years without any serious treatment-related toxicity, while continuing to derive clinical benefit.
Our results are similar to the reported outcomes with paclitaxel in pancreatic cancer. 16 Paclitaxel was tested by Oettle and colleagues as the second-line monotherapy in 18 patients and the toxicity profile, like ours, was generally mild and manageable. The efficacy was also similar in that trial, with 1 patient achieving CR and another 5 patients with SD. A smaller study reporting outcomes of 10 patients treated with docetaxel as second-line monotherapy found no responses, 17 but more encouraging results have been seen with docetaxel combination therapy. 18 SPARC as a predictive biomarker for response to nabpaclitaxel has been studied by Von Hoff et al. 12 In their trial, 32 of 67 patients enrolled, had tumor specimens available for SPARC testing by IHC. The response rate for patients whose tumor cells were SPARC positive versus SPARC negative was 80% versus 36% (P = 0.027). Interestingly SPARC positivity in the stroma did not have any significant correlation with the response. A more recent analysis of the specimens in this trial found that a SPARC microenvironment signature could separate patients into low-risk and high-risk groups, with different outcomes after the nab-paclitaxel and gemcitabine combination therapy. 19 In our trial, the correlation between SPARC expression and outcome was inconclusive. Our analysis was weakened by the small sample size and the lack of tissue for testing on some key specimens. Three of the 7 patients who had clinical benefit from therapy did not have sufficient tumor tissue left for testing. Furthermore, it is not known whether SPARC expression at the time of diagnosis changes with the exposure to first-line chemotherapy, and it is also not clear whether IHC is the most appropriate assay for SPARC, and more work needs to be done to better define the role of this biomarker. The other surrogate marker examined in the present study was CA19-9. For those patients who had an elevated CA19-9 at baseline, a 50% reduction on therapy was associated with prolonged OS.
The main limitation of the present study was the small sample size which led to inconclusive results. Although we considered expanding our study to overcome this limitation, the results of the phase I/II study of gemcitabine combined with nab-paclitaxel were reported at the same time we finished accrual to our study. 12 As the results of the combination appeared to be more promising and a frontline phase III trial was already being planned, our second-line monotherapy study was not expanded.
In summary, nab-paclitaxel monotherapy showed preliminary evidence of activity in a subset of the patients in this trial and was well tolerated. An ongoing phase III trial comparing the combination of gemcitabine and nab-paclitaxel to single-agent gemcitabine as first-line therapy in metastatic pancreatic cancer will better define the role of nab-paclitaxel in this disease.
